• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

由于对基于多替拉韦的抗逆转录病毒联合疗法依从性低导致G118R泛整合酶耐药突变的出现。

Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART.

作者信息

Mens Helene, Fjordside Lasse, Fonager Jannik, Gerstoft Jan

机构信息

Rigshospitalet, Department of Infectious Diseases, 2100 Copenhagen, Denmark.

Viruses and Microbial Special Diagnostics, Statens Serum Institut, 2300 Copenhagen, Denmark.

出版信息

Infect Dis Rep. 2022 Jun 22;14(4):501-504. doi: 10.3390/idr14040053.

DOI:10.3390/idr14040053
PMID:35893472
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9326666/
Abstract

HIV-1 resistance towards integrase inhibitors is a potential threat of the success of HIV-1 combination treatment. G118R is a rare drug resistance mutation conferring pan-integrase resistance. Here, we describe the occurrence of G118R in a HIV-1 subtype-B-positive individual with major compliance problems, detected while the patient was on dolutegravir-based cART. We speculate the pre-selection of M184I/V aided the occurrence of G118R in this case, and discuss the robustness of dolutegravir-based therapies.

摘要

HIV-1对整合酶抑制剂产生耐药性是HIV-1联合治疗成功的一个潜在威胁。G118R是一种罕见的耐药突变，可导致泛整合酶耐药。在此，我们描述了在一名存在严重依从性问题的HIV-1 B亚型阳性个体中检测到G118R的情况，该个体当时正在接受基于多替拉韦的抗逆转录病毒治疗。我们推测M184I/V的预先选择促成了该病例中G118R的出现，并讨论了基于多替拉韦疗法的稳健性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea67/9326666/060549eb9e3a/idr-14-00053-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea67/9326666/c9b07761e444/idr-14-00053-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea67/9326666/060549eb9e3a/idr-14-00053-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea67/9326666/c9b07761e444/idr-14-00053-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea67/9326666/060549eb9e3a/idr-14-00053-g002.jpg

相似文献

1
Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART.由于对基于多替拉韦的抗逆转录病毒联合疗法依从性低导致G118R泛整合酶耐药突变的出现。
Infect Dis Rep. 2022 Jun 22;14(4):501-504. doi: 10.3390/idr14040053.
2
Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.在改用多替拉韦单药治疗后，HIV-1整合酶中出现G118R突变，导致对整合酶抑制剂产生交叉耐药。
J Antimicrob Chemother. 2016 Jul;71(7):1948-53. doi: 10.1093/jac/dkw071. Epub 2016 Mar 29.
3
Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.HIV整合酶不同亚型中G118R、H51Y和E138K耐药性替代的差异效应
J Virol. 2015 Mar;89(6):3163-75. doi: 10.1128/JVI.03353-14. Epub 2014 Dec 31.
4
Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.HIV-1 整合酶中 G118R 相关的多替拉韦耐药突变体的作用的生化分析。
Antimicrob Agents Chemother. 2013 Dec;57(12):6223-35. doi: 10.1128/AAC.01835-13. Epub 2013 Sep 30.
5
HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report.HIV-1 对多替拉韦的耐药性随不规律的治疗依从性而迅速波动：一例报告。
J Glob Antimicrob Resist. 2022 Dec;31:323-327. doi: 10.1016/j.jgar.2022.11.001. Epub 2022 Nov 5.
6
New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.新型拉替拉韦耐药途径可导致对所有目前使用的整合酶抑制剂产生广泛的交叉耐药。
J Antimicrob Chemother. 2014 Aug;69(8):2118-22. doi: 10.1093/jac/dku095. Epub 2014 Apr 7.
7
The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.HIV-1整合酶中的多替拉韦R263K耐药突变与对拉替拉韦耐药性的出现不相容。
AIDS. 2015 Nov;29(17):2255-60. doi: 10.1097/QAD.0000000000000866.
8
The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir.HIV-1中的M184I/V和K65R核苷耐药性突变可防止出现对多替拉韦的耐药性突变。
AIDS. 2016 Sep 24;30(15):2267-73. doi: 10.1097/QAD.0000000000001191.
9
Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.HIV-2 患者在使用雷特格韦失败时出现的耐药突变及其对多替拉韦反应的影响。
J Antimicrob Chemother. 2017 Jul 1;72(7):2083-2088. doi: 10.1093/jac/dkx090.
10
G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance.G118R 和 F121Y 突变在拉替拉韦治疗失败的患者中被发现，可导致多替拉韦耐药。
J Antimicrob Chemother. 2015 Mar;70(3):739-49. doi: 10.1093/jac/dku474. Epub 2014 Nov 20.

引用本文的文献

1
Mutation patterns of integrase gene affect antiretroviral resistance in various non-B subtypes of human immunodeficiency virus Type-1 and their implications for patients' therapy.整合酶基因突变模式对1型人类免疫缺陷病毒多种非B亚型抗逆转录病毒耐药性的影响及其对患者治疗的意义。
Biomedicine (Taipei). 2023 Dec 1;13(4):1-9. doi: 10.37796/2211-8039.1422. eCollection 2023.
2
-Substituted Bicyclic Carbamoyl Pyridones: Integrase Strand Transfer Inhibitors that Potently Inhibit Drug-Resistant HIV-1 Integrase Mutants.取代的双环氨基甲酰基吡啶酮：整合酶链转移抑制剂，能有效抑制耐药 HIV-1 整合酶突变体。
ACS Infect Dis. 2024 Mar 8;10(3):917-927. doi: 10.1021/acsinfecdis.3c00525. Epub 2024 Feb 12.
3

本文引用的文献

1
Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.在 IMPAACT P1093 研究中，来自儿科人群的 HIV-1 整合酶对多替拉韦治疗的耐药性出现。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0164521. doi: 10.1128/AAC.01645-21. Epub 2021 Oct 25.
2
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice.核苷类逆转录酶抑制剂耐药突变可预测临床实践中接受拉米夫定联合多替拉韦维持治疗的人类免疫缺陷病毒阳性患者的病毒学失败。
Open Forum Infect Dis. 2021 Mar 6;8(7):ofab103. doi: 10.1093/ofid/ofab103. eCollection 2021 Jul.
3
Affordable drug resistance genotyping of HIV-1 reverse transcriptase, protease and integrase genes, for resource limited settings.
适用于资源有限环境的 HIV-1 逆转录酶、蛋白酶和整合酶基因的经济耐药性基因分型。
AIDS Res Ther. 2023 Feb 9;20(1):9. doi: 10.1186/s12981-023-00505-3.
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.多替拉韦或达芦那韦联合齐多夫定或替诺福韦治疗HIV
N Engl J Med. 2021 Jul 22;385(4):330-341. doi: 10.1056/NEJMoa2101609.
4
Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.在一项法国全国性调查中，与接受双重或三重整合酶抑制剂方案治疗失败的患者中出现整合酶耐药突变相关的因素。
J Antimicrob Chemother. 2021 Aug 12;76(9):2400-2406. doi: 10.1093/jac/dkab193.
5
Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.在预先存在 M184V/I 突变的治疗经验患者中，含有多替拉韦的三联疗法中出现对整合酶链转移抑制剂的耐药性。
Viruses. 2020 Nov 19;12(11):1330. doi: 10.3390/v12111330.
6
Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients.M184V/I突变对阿巴卡韦/拉米夫定/多替拉韦治疗经治HIV患者疗效的影响
Open Forum Infect Dis. 2019 Jul 12;6(10):ofz330. doi: 10.1093/ofid/ofz330. eCollection 2019 Oct.
7
Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.对整合酶抑制剂的耐药性：一项在 HIV-1 感染的初治和经验治疗患者中的全国性研究。
J Antimicrob Chemother. 2019 May 1;74(5):1368-1375. doi: 10.1093/jac/dkz021.
8
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.多替拉韦加拉米夫定与多替拉韦富马酸酯替诺福韦二吡呋酯和恩曲他滨在初治 HIV-1 感染的成人中的疗效比较（GEMINI-1 和 GEMINI-2）：两项多中心、双盲、随机、非劣效性、3 期临床试验的第 48 周结果。
Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9.
9
Dolutegravir resistance mutations: lessons from monotherapy studies.多替拉韦耐药突变：单药治疗研究的经验教训。
Curr Opin Infect Dis. 2018 Jun;31(3):237-245. doi: 10.1097/QCO.0000000000000453.
10
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.ACTG A5353：多替拉韦加拉米夫定用于治疗 HIV-1 载量<500000 拷贝/mL 的初治 HIV-1 感染者的一项先导研究。
Clin Infect Dis. 2018 May 17;66(11):1689-1697. doi: 10.1093/cid/cix1083.